A carregar...

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Hardin, Elizabeth Ashley, Chin, Kelly M
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5117890/
https://ncbi.nlm.nih.gov/pubmed/27895464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S103534
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!